Recruiting Clinical Trials
Institute | Protocol No. | Trial name | Cancer Site | Experimental Treatment Agent | Key Eligibility Criteria | Principal Investigator | Study Coordinator Contact |
---|---|---|---|---|---|---|---|
HKU |
ALTA-3 |
A Phase 3 Randomized Open-label Study of Brigatinib (Alunbrig®) Versus Alectinib (Alecensa®) in Advanced Anaplastic Lymphoma Kinase-Positive Non Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (Xalkori®) |
NSCLC (ALK-positive) |
Brigatinib vs Alectinib |
1. ALK-positive NSCLC |
Dr Victor LEE |
2255 5034 |
HKU |
ARC-10 |
A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB 154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Locally Advanced / Metastatic NSCLC |
Zimberelimab (AB 122) vs Standard Chemotherapy / Zimberelimab + AB 154 |
1. Histologically confirmed, treatment naïve, locally advanced or metastatic (Stage IIIB - IV), squamous or non-squamous NSCLC with documented high PD-L1 Expression |
Dr Victor LEE |
Kit CHEUNG 2255 5034 |
HKU |
CACZ885T2301 |
A phase III, multicenter, randomized, double bliknd, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v.8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) |
II-IIIA and IIIB (T>5cm N2) completely resected NSCLC |
Canakinumab vs Placebo |
Completely resected stage IIA-IIIB NSCLC who received cisplatin-based chemotherapy and no radiation therapy |
Dr Victor LEE |
Mike LAW 2255 5124 |
HKU |
CGX1321-102 |
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects with Advanced Gastrointestinal Tumors |
Gastrointestinal tumor |
CGX1321 |
Histologically-diagnosed advanced GI tumors with confirmed genetic alterations (e.g., Rspo2 fusion, Rspo3 fusion or predicted loss-of-function mutations in RNF43) upstream in the WNT pathway and no predicted change-of-function alterations in genes (e.g., APC, CTNNB1 and Axin1) downstream in the WNT pathway, that have relapsed or are refractory to or are not considered medically suitable to receive standard of care treatment |
Dr LAM Ka On |
Joyce FAN / Peony LAU 2255 4216 |
HKU |
Cullinan-Pearl |
A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations |
NSCLC (Exon 20 mutated) |
CLN-081 |
1. Documented EGFR exon 20 insertion mutation demonstrated by a test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory. |
Dr Victor LEE |
Kit CHEUNG 2255 5034 |
HKU+QMH |
CVPM087A2101 |
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma |
A: Colorectal (1st line) |
A: Gevokizumab + Bev + FOLFOX 6 |
A: Colorectal (1st line) |
Dr LAM Ka On |
Joyce FAN / Peony LAU 2255 4216 |
HKU |
D933YC00001 (Pacific-5) |
A Phase III, Randomised, Double-Blind, Placebo-Controlled Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy |
NSCLC |
Durvalumab vs Placebo |
1. Documented NSCLC and present with locally advanced, unresectable (Stage III) disease; |
Dr Victor LEE |
Annie WONG 2255 5362 |
HKU + QMH |
EF24 |
LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fildes (TT Fields) concurrent with standard of care therapies for treatment of Stage4 NSCLC following platinum failure |
NSCLC |
TT fields |
Dr Victor LEE |
Kit CHEUNG 2255 5034 |
|
HKU |
EMERALD-2 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation |
Hepatocellular carcinoma (HCC) |
A. Durvaumab + Bevacizumab B. Durvaumab + Bevacizumab placebo C. Durvaumab placebo + Bevacizumab placebo |
Inclusion Criteria: |
Dr CHIANG Chi Leung |
Yuuki TAM 2255 5123 |
HKU |
MK-3475-859 |
A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus palcebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859) |
Stomach / GEJ Cancer |
Pembrolizumab + Xelox vs Placebo + Xelox |
1st line treatment for inoperable, advanced or metastatic GC or GEJ carcinoma, Her2 -ve |
Dr LAM Ka On |
Joyce FAN / Peony LAU 2255 4216 |
HKU |
MK-3475-975 |
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) |
Esophageal Carcinoma |
Pembrolizumab + Chemoradiotherapy vs Placebo + Chemoradiotherapy |
1. Receiving concurrent definitive chemoradiotherapy |
Prof Dora KWONG |
Bryce TANG 2255 4216 |
HKU |
RAIN-701 |
A Phase 2 Study to Evaluate the Clinical Activity of Tarloxotinib in Patients with Non-Small Cell Lung Cancer that Harbors Either an EGFR Exon 20 Insertion or a HER2-Activating Mutation and Other Advanced Solid Tumors with NRG1/ERBB Family Gene Fusions |
Cohort B: HER2-activating mutation Cohort C: NRG1 or ERBB/HER-family gene fusions |
Tarloxotinib |
1. Stage IV, III B or III C NSCLC or recurrent disease with progression / platinum-based chemotherapy OR locally advanced or metastatic solid tumor with progression after SOC |
Dr Victor LEE |
Annie WONG 2255 5362 |
HKU |
START-FIT double IO |
Sequential TransArterial chemoembolization and stereotactic RadioTherapy Followed by Durvalumab (MEDI4736) and Tremelimumab for downstaging hepatocellular carcinoma for hepatectomy |
Hepatocellular carcinoma (HCC) |
TACE + SBRT + Durvalimab and Tremelimumab |
1. Tumour size 5-15 cm and number of lesions ≤3 |
Dr CHIANG Chi Leung |
Yuuki TAM 2255 5125 |
HKU + QMH |
XL184311 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy |
Thyroid Cancer |
Cabozantinib (XL 184) vs Placebo |
1. Histologically or cytologically confirmed diagnosis of Differentiated Thyroid Cancer (DTC) |
Dr Wendy CHAN |
Oscar LEUNG / Tricia HO 2255 4216 |
HKU |
YO42138 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma |
Esophageal Carcinoma |
Ateolizumab + Tiragolumab + Paclitaxel + Cisplatin vs Paclitaxel + Cisplatin |
1. Patients With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma |
Dr LAM Ka On |
Joyce FAN / Peony LAU 2255 4216 |
HKU |
ZL-8301-001 |
A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma |
Gastric/GEJ (1st line) |
TT-Fields + Xelox |
Histologically confirmed unresectable, locally advanced or metastatic Gastroesophageal Junction (GEJ) or Gastric (GC) Adenocarcinoma. The subject must be previously untreated with systemic treatment (including chemotherapy, targeted therapy, and Onco-Immunotherapy), and without resection of primary gastric focu |
Dr LAM Ka On |
Joyce FAN / Peony LAU 2255 4216 |